Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
PLoS One. 2020 Dec 14;15(12):e0243780. doi: 10.1371/journal.pone.0243780. eCollection 2020.
The purpose of this study was to investigate the effect of acute kidney injury (AKI) on the prognosis of patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). A total of 347 HCC patients with Child-Pugh class A and pre-TACE serum creatinine (SCr) ≤1.5 mg/dL undergoing TACE as an initial therapy 2000-2014 were analyzed. Overall survival with related risk factors including AKI was investigated. We assessed AKI based on the International Club of Ascites (ICA)-AKI criteria. The mean age was 60.9 years. Of 347 patients, death was observed in 109 patients (31.4%). The mean SCr levels at pre-TACE, one day, two months, and four months after TACE were 0.9, 0.9, 0.9, and 1.1 mg/dL, respectively. The AKI within four months after TACE developed in 37 patients (11%). The AKI stages were non-AKI in 310 (89%), stage 1 in 10 (3%), stage 2 in 10 (3%), and stage 3 in 17 patients (5%). Multivariable analysis showed that the risk factors for overall survival were serum albumin ≤3.5 g/dL (hazard ratio [HR] 1.58, p = 0.027), BCLC stage B (HR 2.07, p = 0.008), BCLC stage C (HR 3.96, p<0.001), bilobar tumor location (HR 1.66, p = 0.022), AKI stage 1 (HR 6.09, p<0.001), AKI stage 2 (HR 8.51, p<0.001), and AKI stage 3 (HR 17.64, p<0.001). AKI is a crucial prognostic factor for overall survival in HCC patients undergoing TACE. The assessment of AKI based on the ICA-AKI criteria can facilitate evaluation of the prognosis of HCC patients undergoing TACE.
本研究旨在探讨急性肾损伤(AKI)对接受经导管肝动脉化疗栓塞术(TACE)治疗的肝细胞癌(HCC)患者预后的影响。分析了 2000 年至 2014 年间共 347 例 Child-Pugh 分级为 A 级且 TACE 前血清肌酐(SCr)≤1.5mg/dL 的 HCC 患者,这些患者均接受 TACE 作为初始治疗。对包括 AKI 在内的相关危险因素与总生存率进行了研究。我们根据国际腹水俱乐部(ICA)-AKI 标准评估 AKI。患者平均年龄为 60.9 岁。347 例患者中,有 109 例(31.4%)死亡。TACE 前、第 1 天、第 2 个月和第 4 个月的平均 SCr 水平分别为 0.9、0.9、0.9 和 1.1mg/dL。TACE 后 4 个月内有 37 例(11%)发生 AKI。AKI 分期为非 AKI 310 例(89%),1 期 10 例(3%),2 期 10 例(3%),3 期 17 例(5%)。多变量分析显示,总生存率的危险因素包括血清白蛋白≤3.5g/dL(风险比[HR]1.58,p=0.027)、BCLC 分期 B(HR 2.07,p=0.008)、BCLC 分期 C(HR 3.96,p<0.001)、双叶肿瘤位置(HR 1.66,p=0.022)、AKI 分期 1(HR 6.09,p<0.001)、AKI 分期 2(HR 8.51,p<0.001)和 AKI 分期 3(HR 17.64,p<0.001)。AKI 是 TACE 治疗 HCC 患者总生存率的一个关键预后因素。基于 ICA-AKI 标准评估 AKI 有助于评估 TACE 治疗 HCC 患者的预后。